All Outputs (2)

A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance (2015)
Journal Article
Urbanowicz, R. A., McClure, P., Brown, R. J., Tsoleridis, T., Persson, M. A., Krey, T., …Tarr, A. W. (2016). A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance. Journal of Virology, 90(7), 3288-3301. https://doi.org/10.1128/JVI.02700-15

Despite significant advances in the treatment of hepatitis C virus (HCV) infection, the need to develop preventative vaccines remains. Identification of the best vaccine candidates and evaluation of their performance in preclinical and clinical devel... Read More about A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance.

Structural flexibility of a conserved antigenic region in Hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies (2015)
Journal Article
Meola, A., Tarr, A. V., England, P., Meredith, L. W., McClure, P., Foung, S. K., …Krey, T. (2015). Structural flexibility of a conserved antigenic region in Hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. Journal of Virology, 89(4), 2170-2181. https://doi.org/10.1128/JVI.02190-14

Neutralizing antibodies (NAbs) targeting glycoprotein E2 are important for the control of hepatitis C virus (HCV) infection. One conserved antigenic site (amino acids 412 to 423) is disordered in the reported E2 structure, but a synthetic peptide mim... Read More about Structural flexibility of a conserved antigenic region in Hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.